The nation of Zimbabwe has declined a major American health deal valued at $367m (£272m) over five years because of Washington's request for sensitive data.
This rejection came to light after a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official representative later clarified that the US was demanding access to genetic material for scientific study and commercial purposes but was unwilling to guarantee the benefits from any future treatments.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued talks to reach a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court blocked a similar health funding agreement following concerns were filed about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and accountability.
Based on reports, 16 African countries have so far signed these new agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our people if a new health crisis emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were disrupting frameworks already established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This system is intended to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how subsequent collaboration might be designed in a manner that honours the independence and dignity of each country."
Medical Community Reaction
Medical experts expressed it understood the government's concerns, but urged that talks need to persist considering much of the nation's Aids initiatives depended on international support.
"In cases where specific concerns exist, such as those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
The situation underscores the continuing tensions between accepting much-needed international aid and protecting national sovereignty in an ever more interconnected world.